Shareholders’ rights law firm Hagens Berman has opened an investigation into whether Stryker Corporation adequately disclosed a persistent manufacturing issue in its Peripheral Vascular unit.
Stryker’s share price fell significantly on September 8, 2026, after CFO remarks at a conference suggested the problem was ongoing, contrary to previous indications. The issue has reportedly hindered the company’s ability to maintain a full supply of inventory and pursue new business.
The investigation will examine whether Stryker was sufficiently transparent with investors about the problem’s extent and duration. News of the investigation on October 1, 2026, brought further scrutiny to the company’s handling of the matter.